Questions regarding the predictive value of one evolved complex adaptive system for a second: Exemplified by the SOD1 mouse

Progress in Biophysics and Molecular Biology

Volumn 113, Issue 2, 2013, Pages 231-253

  Greek, Ray ^a   Hansen, Lawrence A ^b  

^a Americans For Medical Advancement   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ALS; Animal models; Complex systems; Evolution; Predictive value; SOD1 mouse

Indexed keywords

ANIMALIA;

COPPER ZINC SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE;

ADAPTATION; ALS; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; ANIMAL MODELS; BIOLOGICAL MODEL; BRAIN; COMPLEX SYSTEMS; COMPUTER SIMULATION; DISEASE MODEL; EVOLUTION; GENETICS; HUMAN; MOUSE; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; REVIEW; SOD1 MOUSE; TRANSGENIC MOUSE;

ALS; ANIMAL MODELS; COMPLEX SYSTEMS; EVOLUTION; PREDICTIVE VALUE; SOD1 MOUSE;

ADAPTATION, PHYSIOLOGICAL; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BRAIN; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; MODELS, GENETIC; NEURONAL PLASTICITY; SUPEROXIDE DISMUTASE;

EID: 84887611790     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2013.06.002     Document Type: Review

References (365)

1. Abelson P.H. Exaggerated carcinogenicity of chemicals. Science 1992, 256:1609. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dRetrieve%26db%3dPubMed%26dopt%3dCitation%26list_uids%3d1609271.
2. Acevedo-Arozena A., Kalmar B., Essa S., Ricketts T., Joyce P., Kent R., Rowe C., Parker A., Gray A., Hafezparast M., Thorpe J.R., Greensmith L., Fisher E.M.C. Acomprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis. Dis. Models Mech. 2011, 4:686-700. http://dmm.biologists.org/content/4/5/686.abstract.
3. Afifi A.K., Aleu F.P., Goodgold J., MacKay B. Ultrastructure of atrophic muscle in amyotrophic lateral sclerosis. Neurology 1966, 16:475-481. http://www.ncbi.nlm.nih.gov/pubmed/5949060.
4. Ahl V., Allen T.F.H. Hierarchy Theory, a Vision, Vocabulary and Epistemology 1996, Columbia University Press, New York.
5. Ahn A.C., Tewari M., Poon C.S., Phillips R.S. The limits of reductionism in medicine: could systems biology offer an alternative?. PLoS Med. 2006, 3:e208. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dRetrieve%26db%3dPubMed%26dopt%3dCitation%26list_uids%3d16681415.
6. Aird W.C. Endothelial cell dynamics and complexity theory. Crit. Care Med. 2002, 30:S180-S185. http://www.ncbi.nlm.nih.gov/pubmed/12004233.
7. Albani S., Prakken B. The advancement of translational medicine - from regional challenges to global solutions. Nat. Med. 2009, 15:1006-1009. http://dx.doi.org/10.1038/nm0909-1006.
8. Alexanderson B., Borga O. Interindividual differences in plasma protein binding of nortriptyline in man - a twin study. Eur. J. Clin. Pharmacol. 1972, 4:196-200. http://dx.doi.org/10.1007/BF00635795.
9. Allen P., Greeves M. Paul Allen: the Singularity Isn't Near 2011, http://www.technologyreview.com/view/425733/paul-allen-the-singularity-isnt-near/.
10. Alm E., Arkin A.P. Biological networks. Curr. Opin. Struct. Biol. 2003, 13:193-202. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dRetrieve%26db%3dPubMed%26dopt%3dCitation%26list_uids%3d12727512.
11. Anisimov V.N., Ukraintseva S.V., Yashin A.I. Cancer in rodents: does it tell us about cancer in humans?. Nat. Rev. Cancer 2005, 5:807-819. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dRetrieve%26db%3dPubMed%26dopt%3dCitation%26list_uids%3d16195752.
12. Arrowsmith J. Trial watch: phase II failures: 2008-2010. Nat. Rev. Drug Discov. 2011, 10:328-329. http://dx.doi.org/10.1038/nrd3439.
13. Arrowsmith J. Trial watch: phase III and submission failures: 2008-2010. Nat. Rev. Drug Discov. 2011, 10:87. http://dx.doi.org/10.1038/nrd3375.
14. Bakircioglu M., Carvalho O.P., Khurshid M., Cox J.J., Tuysuz B., Barak T., Yilmaz S., Caglayan O., Dincer A., Nicholas A.K., Quarrell O., Springell K., Karbani G., Malik S., Gannon C., Sheridan E., Crosier M., Lisgo S.N., Lindsay S., Bilguvar K., Gergely F., Gunel M., Woods C.G. The essential role of centrosomal NDE1 in human cerebral cortex neurogenesis. Am. J. Hum. Genet. 2011, http://www.ncbi.nlm.nih.gov/pubmed/21529752.
15. Ballestar E. Epigenetics lessons from twins: prospects for autoimmune disease. Clin. Rev. Allergy Immunol. 2010, 39:30-41. http://www.ncbi.nlm.nih.gov/pubmed/19653134.
16. Banci L., Bertini I., Cantini F., D'Amelio N., Gaggelli E. Human SOD1 before harboring the catalytic metal: solution structure of copper-depleted, disulfide-reduced form. J.Biol. Chem. 2006, 281:2333-2337. http://www.ncbi.nlm.nih.gov/pubmed/16291742.
17. Bankiewicz K.S. Focal Dopamine Indicated in Dyskinesias in MPTP Monkeys 2006, UCSF, 1R01NS050156-01A2. http://projectreporter.nih.gov/project_info_description.cfm%3faid%3d7148558%26icde%3d15324344.
18. Barber E.D., Teetsel N.M., Kolberg K.F., Guest D. Acomparative study of the rates of invitro percutaneous absorption of eight chemicals using rat and human skin. Fundam. Appl. Toxicol. 1992, 19:493-497. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dRetrieve%26db%3dPubMed%26dopt%3dCitation%26list_uids%3d1426706.
19. Bard J., Melham T., Noble D. Epilogue: some conceptual foundations of systems biology. Prog. Biophys. Mol. Biol. 2012, http://www.ncbi.nlm.nih.gov/pubmed/23274735.
20. Bard J., Melham T., Werner E., Noble D. Plenary discussion of the conceptual foundations of systems biology. Prog. Biophys. Mol. Biol. 2012, http://www.ncbi.nlm.nih.gov/pubmed/23276725.
21. Bari A. Severe toxicity of fialuridine (FIAU). N.Engl. J. Med. 1996, 334:1135. author reply 1137-8. http://www.ncbi.nlm.nih.gov/pubmed/8598879.
22. Barrow-Green J. Poincaré and the Three Body Problem 1997, American Mathematical Society, Providence.
23. Bates S. Progress towards personalized medicine. Drug Discov. Today 2010, 15:115-120.
24. Window into Cancer-spread Secrets November 10, 2008, BBC News. http://news.bbc.co.uk/2/hi/health/7711650.stm.
25. Becskei A., Serrano L. Engineering stability in gene networks by autoregulation. Nature 2000, 405:590-593. http://www.ncbi.nlm.nih.gov/pubmed/10850721.
26. Begley S. We Fought Cancer. and Cancer Won April 24 September 15, 2008, http://www.newsweek.com/id/157548.
27. Begley C.G., Ellis L.M. Drug development: raise standards for preclinical cancer research. Nature 2012, 483:531-533. http://dx.doi.org/10.1038/483531a.
28. Bell J.T., Spector T.D. Atwin approach to unraveling epigenetics. Trends Genet. TIG 2011, 27:116-125.
29. Belmaker R., Bersudsky Y., Agam G. Individual differences and evidence-based psychopharmacology. BMC Med. 2012, 10:110. http://www.ncbi.nlm.nih.gov/pubmed/23016518.
30. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 2007, 26:1-13. http://www.sciencedirect.com/science/article/pii/S0969996106003287.
31. Beniashvili D.S. Experimental Tumors in Monkeys 1994, CRC Press, Boca Raton.
32. Bhathena A., Spear B.B. Pharmacogenetics: improving drug and dose selection. Curr. Opin. Pharmacol. 2008, 8:639-646. http://www.ncbi.nlm.nih.gov/pubmed/18762278.
33. Bickel P.J., Buhlmann P. What is a linear process?. Proc. Natl. Acad. Sci. U S A 1996, 93:12128-12131. http://www.ncbi.nlm.nih.gov/pubmed/8901544.
34. Bizzarri M., Palombo A., Cucina A. Theoretical aspects of systems biology. Prog. Biophys. Mol. Biol. 2013, http://www.ncbi.nlm.nih.gov/pubmed/23562476.
35. Blair E. Predictive tests and personalised medicine. Drug Discov. World 2009, 27-31.
36. Bohm D. Some remarks on the noting of order. Sketches 1969, vol. 2:18-40. Edinburgh Press, Edinburgh. C.H. Waddington (Ed.).
37. Bonati M., Latini R., Tognoni G., Young J.F., Garattini S. Interspecies comparison of invivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug Metab. Rev. 1984, 15:1355-1383. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d6543526.
38. Boyd P.T., Mcmillan S.L.W. Parameter space structure in irregular gravitational scattering. Phys. Rev. 1992, A15:6277-6287.
39. Braithwaite R.B. Scientific Explanation: a Study of the Function of Theory, Probability and Law in Science 1953, Cambridge University Press, Cambridge.
40. Brennan R., Federico S., Dyer M.A. The war on cancer: have we won the battle but lost the war?. Oncotarget 2010, 1:77-83. http://www.ncbi.nlm.nih.gov/pubmed/20877440.
41. Brower V. Epigenetics: unravelling the cancer code. Nature 2011, 471:S12-S13. http://dx.doi.org/10.1038/471s12a.
42. Bruder C.E., Piotrowski A., Gijsbers A.A., Andersson R., Erickson S., De Stahl T.D., Menzel U., Sandgren J., Von Tell D., Poplawski A., Crowley M., Crasto C., Partridge E.C., Tiwari H., Allison D.B., Komorowski J., Van Ommen G.J., Boomsma D.I., Pedersen N.L., Den Dunnen J.T., Wirdefeldt K., Dumanski J.P. Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am. J. Hum. Genet. 2008, 82:763-771. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d18304490.
43. Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., Reaume A.G., Scott R.W., Cleveland D.W. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998, 281:1851-1854. http://www.ncbi.nlm.nih.gov/pubmed/9743498.
44. Bruijn L.I., Miller T.M., Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 2004, 27:723-749. http://www.ncbi.nlm.nih.gov/pubmed/15217349.
45. Buchanan R.W., Keefe R.S., Umbricht D., Green M.F., Laughren T., Marder S.R. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?. Schizophrenia Bull. 2011, 37:1209-1217. http://www.ncbi.nlm.nih.gov/pubmed/20410237.
46. Bugge T.H., Kombrinck K.W., Flick M.J., Daugherty C.C., Danton M.J., Degen J.L. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 1996, 87:709-719. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d8929539.
47. Burggren W.W., Bemis W.E. Studying physiological evolution: paradigms and pitfalls. Evolutionary Innovations 1990, 191-228. University Of Chicago Press, Chicago. M.H. Nitecki (Ed.).
48. Calabrese E.J. Principles of Animal Extrapolation 1991, CRC Press, Boca Raton.
49. Caldwell J. Comparative aspects of detoxification in mammals. Enzymatic Basis of Detoxification 1980, 85-114. Academic Press, New York. W. Jakoby (Ed.).
50. Caldwell J. Problems and opportunities in toxicity testing arising from species differences in xenobiotic metabolism. Toxicol. Lett. 1992, 64-65. Spec No, 651-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d1471219.
51. Canto J.G., Rogers W.J., Goldberg R.J., Peterson E.D., Wenger N.K., Vaccarino V., Kiefe C.I., Frederick P.D., Sopko G., Zheng Z.-J. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA: J. Am. Med. Assoc. 2012, 307:813-822. http://jama.ama-assn.org/content/307/8/813.abstract.
52. Caponigro G., Sellers W.R. Advances in the preclinical testing of cancer therapeutic hypotheses. Nat. Rev. Drug Discov. 2011, 10:179-187. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d21358737.
53. Carbone L. The utility of basic animal research. Hastings Center Rep. Suppl. 2012, S12-S15. http://www.ncbi.nlm.nih.gov/pubmed/23138422.
54. Chapman S.J., Hill A.V.S. Human genetic susceptibility to infectious disease. Nat. Rev. Genet. 2012, 13:175-188. http://dx.doi.org/10.1038/nrg3114.
55. Charcot J. Sclérose Des Cordons Latéraux De La Moelle Épinière Chez Une Femme Hystérique Atteinte De Contracture Permanente Des Quatre Membres. Bull. Soc. Méd. Des. HÔpit. Paris 1865, 10:24-35.
56. Charcot J. Amyotrophies Spinales Deuteropathiques Sclérose Latérale Amyotrophique & Sclérose Latérale Amyotrophique. Bureaux Prog. Méd. 1874, 2:234-266.
57. Chattopadhyay M., Valentine J.S. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid. Redox Signal. 2009, 11:1603-1614.
58. Cheung D.S., Warman M.L., Mulliken J.B. Hemangioma in twins. Ann. Plast. Surg. 1997, 38:269-274. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d9088466.
59. Clemmensen J., Hjalgrim-Jensen S. On the absence of carcinogenicity to man of phenobarbital. Human Epidemiology andAnimal Laboratory Correlations in Chemical Carcinogenesis 1980, 251-265. Alex Pub. F. Coulston, S. Shubick (Eds.).
60. Cleveland D.W., Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS, nature reviews. Neuroscience 2001, 2:806-819. http://www.ncbi.nlm.nih.gov/pubmed/11715057.
61. Cohen P., Coghlan A. Secrets of the genome: less is more. New Sci. 2001, 169:6.
62. Collins F.S. Reengineering translational science: the time is right. Sci. Transl. Med. 2011, 3. 90cm17. http://stm.sciencemag.org/content/3/90/90cm17.abstract.
63. Collins J.M., Mcdevitt D.G., Shanks R.G., Swanton J.G. The cardio-toxicity of isoprenaline during hypoxia. Br. J. Pharmacol. 1969, 36:35-45. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d5768127.
64. Cook N., Jodrell D.I., Tuveson D.A. Predictive invivo animal models and translation to clinical trials. Drug Discov. Today 2012, 17:253-260.
65. Corcia P., Gordon P.H. Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole. Ther. Clin. Risk Manag. 2012, 8:359-366.
66. Corry D.C. Pain in carcinoma of the breast. Lancet 1952, 1:274-276. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d14889840.
67. Couzin J. Cancer research. Probing the roots of race and cancer. Science 2007, 315:592-594. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d17272699.
68. Cozzolino M., Ferri A., Carri M.T. Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. Antioxid. Redox Signal. 2008, 10:405-443. http://www.ncbi.nlm.nih.gov/pubmed/18370853.
69. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013, Cross-Disorder Group Of The Psychiatric Genomics Consortium. http://linkinghub.elsevier.com/retrieve/pii/s0140673612621291.
70. Crowley W.F. Translation of basic research into useful treatments: how often does it occur?. Am. J. Med. 2003, 114:503-505. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d12727585.
71. Csete M.E., Doyle J.C. Reverse engineering of biological complexity. Science 2002, 295:1664-1669. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d11872830.
72. Longer Tests on Lab Animals Urged for Potential Carcinogens November 17, 2008, CSPI. http://www.cspinet.org/new/200811172.html.
73. Czyz W., Morahan J., Ebers G., Ramagopalan S. Genetic, environmental and stochastic factors in monozygotic twin discordance with a focus on epigenetic differences. BMC Med. 2012, 10:93. http://www.biomedcentral.com/1741-7015/10/93.
74. Daly A.K. Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet. 2010, 11:241-246. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d20300088.
75. Danzeisen R., Schwalenstoecker B., Gillardon F., Buerger E., Krzykalla V., Klinder K., Schild L., Hengerer B., Ludolph A.C., Dorner-Ciossek C., Kussmaul L. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-lpropylamino-benzathiazole dihydrochloride]. J.Pharmacol. Exp. Ther. 2006, 316:189-199. http://www.ncbi.nlm.nih.gov/pubmed/16188953.
76. Davalos L.M., Cirranello A.L., Geisler J.H., Simmons N.B. Understanding phylogenetic incongruence: lessons from phyllostomid bats. Biol. Rev. Camb. Philos. Soc. 2012.
77. Dempster E.L., Pidsley R., Schalkwyk L.C., Owens S., Georgiades A., Kane F., Kalidindi S., Picchioni M., Kravariti E., Toulopoulou T., Murray R.M., Mill J. Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum. Mol. Genet. 2011, 20:4786-4796. http://www.ncbi.nlm.nih.gov/pubmed/21908516.
78. Deng H.X., Hentati A., Tainer J.A., Iqbal Z., Cayabyab A., Hung W.Y., Getzoff E.D., Hu P., Herzfeldt B., Roos R.P., et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 1993, 261:1047-1051. http://www.ncbi.nlm.nih.gov/pubmed/8351519.
79. Deng H.X., Shi Y., Furukawa Y., Zhai H., Fu R., Liu E., Gorrie G.H., Khan M.S., Hung W.Y., Bigio E.H., Lukas T., Dal Canto M.C., O'Halloran T.V., Siddique T. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc. Natl. Acad. Sci. U S A 2006, 103:7142-7147. http://www.ncbi.nlm.nih.gov/pubmed/16636275.
80. Devoy A., Bunton-Stasyshyn R.K.A., Tybulewicz V.L.J., Smith A.J.H., Fisher E.M.C. Genomically humanized mice: technologies and promises. Nat. Rev. Genet. 2012, 13:14-20. http://dx.doi.org/10.1038/nrg3116.
81. Di Carlo F.J. Carcinogenesis bioassay data: correlation by species and sex. Drug Metab. Rev. 1984, 15:409-413. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d6489158.
82. Dias A.S., Bester M.J., Britz R.F., Apostolides Z. Animal models used for the evaluation of antiretroviral therapies. Curr. HIV Res. 2006, 4:431-446. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d17073618.
83. Dimasi J.A., Grabowski H.G. Economics of new oncology drug development. J.Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007, 25:209-216. http://www.ncbi.nlm.nih.gov/pubmed/17210942.
84. Dimasi J.A., Feldman L., Seckler A., Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 2010, 87:272-277. http://www.ncbi.nlm.nih.gov/pubmed/20130567.
85. Dion P.A., Daoud H., Rouleau G.A. Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat. Rev. Genet. 2009, 10:769-782. http://www.ncbi.nlm.nih.gov/pubmed/19823194.
86. Dixit R., Boelsterli U. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discov. Today 2007, 12:336-342.
87. Djinovic Carugo K., Battistoni A., Carri M.T., Polticelli F., Desideri A., Rotilio G., Coda A., Wilson K.S., Bolognesi M. Three-dimensional structure of xenopus laevis Cu, Zn superoxide dismutase B determined by X-ray crystallography at 1.5A resolution. Acta Crystallogr. Sect. D, Biol. Crystallogr. 1996, 52:176-188. http://www.ncbi.nlm.nih.gov/pubmed/15299740.
88. Djinovic K., Gatti G., Coda A., Antolini L., Pelosi G., Desideri A., Falconi M., Marmocchi F., Rotilio G., Bolognesi M. Crystal structure of yeast Cu/Zn superoxide dismutase. Crystallographic refinement at 2.5A resolution. J.Mol. Biol. 1992, 225:791-809. http://www.ncbi.nlm.nih.gov/pubmed/1602482.
89. Dobzhansky T. Nothing in biology makes sense except in the light of evolution. Am. Biol. Teach. 1973, 35:125-129.
90. Dolgin E. Big pharma moves from 'blockbusters' to 'niche busters'. Nat. Med. 2010, 16:837. http://dx.doi.org/10.1038/nm0810-837a.
91. Drake D.R., Singh I., Nguyen M.N., Kachurin A., Wittman V., Parkhill R., Kachurina O., Moser J.M., Burdin N., Moreau M., Mistretta N., Byers A.M., Dhir V., Tapia T.M., Vernhes C., Gangur J., Kamala T., Swaminathan N., Warren W.L. Invitro biomimetic model of the human immune system for predictive vaccine assessments. Disruptive Sci. Technol. 2012, 1:28-40.
92. Durrive B. Scientific progress specific to biology: an epistemological overview. Prog. Biophys. Mol. Biol. 2012, 110:17-23. http://www.ncbi.nlm.nih.gov/pubmed/22543274.
93. Dybing E., Sanner T. Species differences in chemical carcinogenesis of the thyroid gland, kidney and urinary bladder. IARC Sci. Publ. 1999, 15-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d10457907.
94. Dolgin E. Animal rule for drug approval creates a jungle of confusion. NatMed. 2013, 19:118-119. http://www.ncbi.nlm.nih.gov/pubmed/23389593.
95. Eason C.T., Bonner F.W., Parke D.V. The importance of pharmacokinetic and receptor studies in drug safety evaluation. Regul. Toxicol. Pharmacol. 1990, 11:288-307. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d2196638.
96. Follow the yellow brick road. Nat. Rev. Drug Discov. 2003, 2:167. Editorial. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d12619635.
97. The end of the beginning?. Nat. Rev. Drug Discov. 2006, 5:705. Editorial. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d17001798.
98. Same old story?. Nat. Rev. Drug Discov. 2007, 6:97. Editorial. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d17342859.
99. Aslippery slope. Nature 2009, 462:699. Editorial.
100. Cancer drugs: remedy required. Nat. Med. 2011, 17:231. Editorial. http://dx.doi.org/10.1038/nm0311-231.
101. Astronger role for science. Nat. Rev. Drug Discov. 2011, 10:159. Editorial. http://www.ncbi.nlm.nih.gov/pubmed/21469392.
102. Nat Rev Drug Discov. 2011, 10:239. Editors, http://dx.doi.org/10.1038/nrd3411, in this issue.
103. Elowitz M.B., Levine A.J., Siggia E.D., Swain P.S. Stochastic gene expression in a single cell. Science 2002, 297:1183-1186. http://www.ncbi.nlm.nih.gov/pubmed/12183631.
104. Ennever F.K., Noonan T.J., Rosenkranz H.S. The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans. Mutagenesis 1987, 2:73-78. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d3331705.
105. Innovation or Stagnation? Challenge and Opportunity on the CriticalPath to New Medical Products 2004, FDA. http://www.Nipte.Org/Docs/Critical_Path.Pdf.
106. FDA Issues Advice to Make Earliest Stages of Clinical Drug Development More Efficient March 7, 2006, FDA, June 18, 2009. http://www.fda.gov/newsevents/newsroom/pressannouncements/2006/ucm108576.htm.
107. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., Mcarthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N.Engl. J. Med. 2010, 363:809-819. http://www.Ncbi.Nlm.Nih.Gov/Entrez/Query.Fcgi%3FCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d20818844.
108. Fletcher A.P. Drug safety tests and subsequent clinical experience. J.R. Soc. Med. 1978, 71:693-696. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d712750.
109. Flintoft L. Epigenetics: identical twins: epigenetics makes the difference. Nat. Rev. Genet. 2005, 6:667.
110. Fomchenko E.I., Holland E.C. Mouse models of brain tumors and their applications in preclinical trials. Clin. Cancer Res. 2006, 12:5288-5297. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d17000661.
111. Force T., Kolaja K.L. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 2011, 10:111-126. http://dx.doi.org/10.1038/Nrd3252.
112. Fox J.G., Thibert P., Arnold D.L., Krewski D.R., Grice H.C. Toxicology studies. II. The laboratory animal. Food Cosmet. Toxicol. 1979, 17:661-675. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d546701.
113. Fraga M.F., Ballestar E., Paz M.F., Ropero S., Setien F., Ballestar M.L., Heine-Suner D., Cigudosa J.C., Urioste M., Benitez J., Boix-Chornet M., Sanchez-Aguilera A., Ling C., Carlsson E., Poulsen P., Vaag A., Stephan Z., Spector T.D., Wu Y.Z., Plass C., Esteller M. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. U S A 2005, 102:10604-10609. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d16009939.
114. Froehlich T.E., Epstein J.N., Nick T.G., Melguizo Castro M.S., Stein M.A., Brinkman W.B., Graham A.J., Langberg J.M., Kahn R.S. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J.Am. Acad. Child Adolesc. Psychiatry 2011, 50. 1129-1139.E2. http://linkinghub.elsevier.com/retrieve/pii/s0890856711006897%3fshowall%3dtrue.
115. Gad S. Model selection and scaling. Animal Models in Toxicology 2006, 831-862. Informa Healthcare, Drug And Chemical Toxicology. Second ed. S. Gad (Ed.).
116. Gad S. Preface. Animal Models in Toxicology 2007, 1-18. CRC Press, Boca Raton. S. Gad (Ed.).
117. Gare A. Overcoming the Newtonian paradigm: the unfinished project of theoretical biology from a Schellingian perspective. Prog. Biophys. Mol. Biol. 2013, http://www.ncbi.nlm.nih.gov/pubmed/23562477.
118. Gibbs R.A., Rogers J., Katze M.G., Bumgarner R., Weinstock G.M., Mardis E.R., Remington K.A., Strausberg R.L., Venter J.C., Wilson R.K., Batzer M.A., Bustamante C.D., Eichler E.E., Hahn M.W., Hardison R.C., Makova K.D., Miller W., Milosavljevic A., Palermo R.E., Siepel A., Sikela J.M., Attaway T., Bell S., Bernard K.E., Buhay C.J., Chandrabose M.N., Dao M., Davis C., Delehaunty K.D., Ding Y., Dinh H.H., Dugan-Rocha S., Fulton L.A., Gabisi R.A., Garner T.T., Godfrey J., Hawes A.C., Hernandez J., Hines S., Holder M., Hume J., Jhangiani S.N., Joshi V., Khan Z.M., Kirkness E.F., Cree A., Fowler R.G., Lee S., Lewis L.R., Li Z., Liu Y.S., Moore S.M., Muzny D., Nazareth L.V., Ngo D.N., Okwuonu G.O., Pai G., Parker D., Paul H.A., Pfannkoch C., Pohl C.S., Rogers Y.H., Ruiz S.J., Sabo A., Santibanez J., Schneider B.W., Smith S.M., Sodergren E., Svatek A.F., Utterback T.R., Vattathil S., Warren W., White C.S., Chinwalla A.T., Feng Y., Halpern A.L., Hillier L.W., Huang X., Minx P., Nelson J.O., Pepin K.H., Qin X., Sutton G.G., Venter E., Walenz B.P., Wallis J.W., Worley K.C., Yang S.P., Jones S.M., Marra M.A., Rocchi M., Schein J.E., Baertsch R., Clarke L., Csuros M., Glasscock J., Harris R.A., Havlak P., Jackson A.R., Jiang H., et al. Evolutionary and biomedical insights from the Rhesus macaque genome. Science 2007, 316:222-234. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d17431167.
119. Gibson E. Q&A: Dr. Keith Cheng, Researcher at Penn State's College of Medicine, Shares Views on Using Animals in Scientific Research May 1, 2012, April 22. http://www.pennlive.com/midstate/index.ssf/2012/04/qa_dr_keith_cheng_researcher_a.html.
120. Giles J. Animal experiments under fire for poor design. Nature 2006, 444:981. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d17183281.
121. Gonzalez F.J., Idle J.R. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin. Pharmacokinet. 1994, 26:59-70. http://www.ncbi.nlm.nih.gov/pubmed/8137598.
122. Goodlett C.R. Testing Fasd Therapeutic Agents: Neonatal Rodent Models 2003, Indiana Univ-Purdue Univ at Indianapolis, 1U01AA014829-01. http://projectreporter.nih.gov/project_info_description.cfm%3faid%3d6743827%26icde%3d15324375%26ddparam%3d%26ddvalue%3d%26ddsub%3d%26cr%3d1%26csb%3ddefault%26cs%3dasc.
123. Goodwin B. How the Leopard Changed Its Spots: the Evolution of Complexity 2001, Princeton University Press, Princeton.
124. Gordon L., Joo J.H., Andronikos R., Ollikainen M., Wallace E.M., Umstad M.P., Permezel M., Oshlack A., Morley R., Carlin J.B., Saffery R., Smyth G.K., Craig J.M. Expression discordance of monozygotic twins at birth: effect of intrauterine environment and a possible mechanism for fetal programming. Epigenetics 2011, 6:579-592.
125. Gosden R.G., Feinberg A.P. Genetics and epigenetics - nature's pen-and-pencil set. N.Engl. J. Med. 2007, 356:731-733. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d17301306.
126. Gould S. Humbled by the Genome's Mysteries February 21, 2001, New York Times.
127. Greek R. Letter. Dogs, genes and drugs. Am. Scientist 2008, 96:4.
128. Greek R. Animal models and the development of an HIV vaccine. J.AIDS Clinic Res. 2012, S8:001.
129. Greek R. Animal models in drug development. New Insights into Toxicity and Drug Testing 2013, 124-152. Intech, Manhattan. S. Gowder (Ed.).
130. Greek R. Animal models of cancer. Light of Evolutionary Biology and Complexity Science, the Research and Biology of Cancer 2013, Iconcept Press, Hong Kong.
131. Greek J., Greek R. What Will We Do if We Don't Experiment on Animals? 2004, Trafford.
132. Greek R., Greek J. Is the use of sentient animals in basic research justifiable?. Philos. Ethics Humanit. Med. 2010, 5:14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3fcmd%3dretrieve%26db%3dpubmed%26dopt%3dcitation%26list_uids%3d20825676.
133. Greek R., Hansen L.A. The development of deep brain stimulation for movement disorders. J.Clinic Res. Bioeth. 2012, 3.
134. Greek R., Pound P. Animal studies and HIV research. BMJ 2002, 324:236-237.
135. Greek R., Rice M.J. Animal models and conserved processes. Theor. Biol. Med. Model. 2012, 9. http://www.tbiomed.com/content/9/1/40/abstract.
136. Greek R., Shanks N. Faqs about the use of animals. Science: a Handbook for the Scientifically Perplexed 2009, University Press Of America, Lanham.
137. Greek R., Shanks N. Complex systems, evolution, and animal models. Stud. Hist. Philos. Biol. Biomed. Sci. 2011, 42:542-544. http://www.Ncbi.Nlm.Nih.Gov/Pubmed/22035727.
138. Greek R., Hansen L.A., Menache A. An analysis of the Bateson review of research using nonhuman primates. Medicolegal Bioeth. 2011, 1:3-22. http://www.Dovepress.Com/An-Analysis-Of-The-Bateson-Review-Of-Research-Using-Nonhuman-Primates-Peer-Reviewed-Article-MB.
139. Greek R., Shanks N., Rice M.J. The history and implications of testing thalidomide on animals. J.Philos. Sci. Law 2011, 11. http://www6.miami.edu/Ethics/Jpsl/Archives/All/Testingthalidomide.Html.
140. Greek R., Menache A., Rice M.J. Animal models in an age of personalized medicine. Personalized Med. 2012, 9:47-64. http://dx.doi.org/10.2217/pme.11.89.
141. Greek R., Pippus A., Hansen L.A. The Nuremberg code subverts human health and safety by requiring animal modeling. BMC Med. Ethics 2012, 13:16. http://www.Ncbi.Nlm.Nih.Gov/Pubmed/22769234.
142. Gregor Z., Joffe L. Senile macular changes in the Black African. Br. J. Ophthalmol. 1978, 62:547-550. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d687553.
143. Gross D.R. Animal Models in Cardiovascular Research 1985, Martinus Nijhoff, The Hague.
144. Grove A.S. Efficiency in the health care industries: a view from the outside. JAMA 2005, 294:490-492. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d16046656.
145. Gur Barzilai M., Reitzel A.M., Kraus J.E.M., Gordon D., Technau U., Gurevitz M., Moran Y. Convergent evolution of sodium ion selectivity in metazoan neuronal signaling. Cell Rep. 2012, http://linkinghub.elsevier.com/Retrieve/Pii/S2211124712001908.
146. Gura T. Cancer models: systems for identifying new drugs are often faulty. Science 1997, 278:1041-1042. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d9381203.
147. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994, 264:1772-1775. http://www.ncbi.nlm.nih.gov/Pubmed/8209258.
148. Habeck M. Of mice and men, and cancer research. Drug Discov. Today 2002, 7:981-982.
149. Hahn W.C., Weinberg R.A. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2002, 2:331-341. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d12044009.
150. Haiman C.A., Stram D.O., Wilkens L.R., Pike M.C., Kolonel L.N., Henderson B.E., Le Marchand L. Ethnic and racial differences in the smoking-related risk of lung cancer. N.Engl. J. Med. 2006, 354:333-342. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d16436765.
151. Hakeem A.Y., Sherwood C.C., Bonar C.J., Butti C., Hof P.R., Allman J.M. Von economo neurons in the elephant brain. Anat. Rec. 2009, 292:242-248. http://www.ncbi.nlm.nih.gov/Pubmed/19089889.
152. Halder A., Jain M., Chaudhary I., Varma B. Chromosome 22q11.2 microdeletion in monozygotic twins with discordant phenotype and deletion size. Mol. Cytogenet. 2012, 5:13. http://www.ncbi.nlm.nih.gov/Pubmed/22413934.
153. Hart P.J., Balbirnie M.M., Ogihara N.L., Nersissian A.M., Weiss M.S., Valentine J.S., Eisenberg D. Astructure-based mechanism for copper-zinc superoxide dismutase. Biochemistry 1999, 38:2167-2178. http://www.ncbi.nlm.nih.gov/Pubmed/10026301.
154. Hart B.A., Abbott D.H., Nakamura K., Fuchs E. The Marmoset monkey: a multi-purpose preclinical and translational model of human biology and disease. Drug Discov. Today 2012, 17:1160-1165. http://www.ncbi.nlm.nih.gov/Pubmed/22728226.
155. Hau J. Animal models. Animal Models 2003, 1-9. CRC Press, Boca Raton. second ed. J. Hau, G.K. Van Hoosier (Eds.).
156. Hormone Lowers Glucose Levels in Mice 11/13/2008, Health Day. http://www.healthday.com/Article.Asp%3fAID%3d620987.
157. Heng H.H. The conflict between complex systems and reductionism. JAMA: J. Am. Med. Assoc. 2008, 300:1580-1581. http://www.ncbi.nlm.nih.gov/Pubmed/18827215.
158. Herndon C.N., Jennings R.G. Atwin-family study of susceptibility to poliomyelitis. Am. J. Hum. Genet. 1951, 3:17-46. http://www.ncbi.nlm.nih.gov/Pubmed/13171372.
159. Heywood R. Clinical toxicity - could it have been predicted? Post-marketing experience. Animal Toxicity Studies: Their Relevance for Man 1990, 57-67. Quay, Lancaster. C.E. Lumley, S. Walker (Eds.).
160. Hirtz D., Thurman D.J., Gwinn-Hardy K., Mohamed M., Chaudhuri A.R., Zalutsky R. How common are the "Common" neurologic disorders?. Neurology 2007, 68:326-337. http://www.ncbi.nlm.nih.gov/Pubmed/17261678.
161. Hitchens C. Mommie Dearest 2003, http://www.slate.com/Articles/News_And_Politics/Fighting_Words/2003/10/Mommie_Dearest.Html.
162. Hochachka P.W., Somero G.N. Biochemical Adaptation: Mechanism and Process in Physiological Evolution 2002, Oxford University Press, Oxford.
163. Hodgkin J. Seven types of pleiotropy. Int. J. Dev. Biol. 1998, 42:501-505. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d9654038.
164. Hof P.R., Van Der Gucht E. Structure of the cerebral cortex of the humpback whale, Megaptera Novaeangliae (Cetacea, Mysticeti, Balaenopteridae). Anat. Rec. 2007, 290:1-31. http://www.ncbi.nlm.nih.gov/Pubmed/17441195.
165. Holden C. Sex and the suffering brain. Science 2005, 308:1574. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d15947170.
166. Holden C. Random samples. Well-wired whales. Science 2006, 314:1363.
167. Holmes B. Monkey genome springs surprise for human origins. New Scientist 2007, 15.
168. Horgan J.F. From complexity to perplexity. Scientific Am. 1995, 104-109.
169. Horrobin D.F. Modern biomedical research: an internally self-consistent universe with little contact with medical reality?. Nat. Rev. Drug Discov. 2003, 2:151-154. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d12563306.
170. Hudson K.L. Genomics, health care, and society. N.Engl. J. Med. 2011, 365:1033-1041. http://www.nejm.org/Doi/Full/10.1056/Nejmra1010517.
171. Huff J., Jacobson M.F., Davis D.L. The limits of two-year bioassay exposure regimens for identifying chemical carcinogens. Environ. Health Perspect. 2008, 116:1439-1442. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d19057693.
172. Hughes B. Industry concern over EU hepatotoxicity guidance. Nat. Rev. Drug Discov. 2008, 7:719. http://dx.doi.org/10.1038/Nrd2677.
173. Hughes A.R., Spreen W.R., Mosteller M., Warren L.L., Lai E.H., Brothers C.H., Cox C., Nelsen A.J., Hughes S., Thorborn D.E., Stancil B., Hetherington S.V., Burns D.K., Roses A.D. Pharmacogenetics of hypersensitivity to Abacavir: from Pgx hypothesis to confirmation to clinical utility. Pharmacogenomics J. 2008, 8:365-374. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d18332899.
174. Hurko O. Understanding the strategic importance of biomarkers for the discovery and early development phases. Drug Discov. World 2006, 63-74.
175. Inman W.H. Monitoring for Drug Safety 1980, MTP Press.
176. Jaarsma D., Teuling E., Haasdijk E.D., De Zeeuw C.I., Hoogenraad C.C. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J.Neurosci.: Off. J. Soc. Neurosci. 2008, 28:2075-2088. http://www.ncbi.nlm.nih.gov/Pubmed/18305242.
177. Javierre B.M., Fernandez A.F., Richter J., Al-Shahrour F., Martin-Subero J.I., Rodriguez-Ubreva J., Berdasco M., Fraga M.F., O'Hanlon T.P., Rider L.G., Jacinto F.V., Lopez-Longo F.J., Dopazo J., Forn M., Peinado M.A., Carreno L., Sawalha A.H., Harley J.B., Siebert R., Esteller M., Miller F.W., Ballestar E. Changes in the pattern of DNA methylation associate with twin discordance in Systemic lupus erythematosus. Genome Res. 2010, 20:170-179. http://genome.cshlp.org/Content/20/2/170.Abstract.
178. Javierre B.M., Fernandez A.F., Richter J., Al-Shahrour F., Martin-Subero J.I., Rodriguez-Ubreva J., Berdasco M., Fraga M.F., O'Hanlon T.P., Rider L.G., Jacinto F.V., Lopez-Longo F.J., Dopazo J., Forn M., Peinado M.A., Carreno L., Sawalha A.H., Harley J.B., Siebert R., Esteller M., Miller F.W., Ballestar E. Changes in the pattern of DNA methylation associate with twin discordance in Systemic lupus erythematosus. Genome Res. 2010, 20:170-179. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d20028698.
179. Jeffrey S. Dexpramipexole Fails in Als February 16, 2013, January 4, 2013. http://www.medscape.com/Viewarticle/777141.
180. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., Kalyandrug S., Christian M., Arbuck S., Hollingshead M., Sausville E.A. Relationships between drug activity in NCI preclinical invitro and invivo models and early clinical trials. Br. J. Cancer 2001, 84:1424-1431. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d11355958.
181. Joyce P.I., Fratta P., Fisher E.M., Acevedo-Arozena A. SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm. Genome Off. J. Int. Mamm. Genome Soc. 2011, 22:420-448. http://www.ncbi.nlm.nih.gov/Pubmed/21706386.
182. Jørgensen J.T. Achallenging drug development process in the era of personalized medicine. Drug Discov. Today 2011, 16:891-897.
183. Kaiser J. Gender in the pharmacy: does it matter?. Science 2005, 308:1572. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d15947169.
184. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol. Sci. 1991, 12:102-107. http://www.ncbi.nlm.nih.gov/Pubmed/2053186.
185. Kamb A. What's wrong with our cancer models?. Nat. Rev. Drug Discov. 2005, 4:161-165. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d15688078.
186. Kastens K.A., Manduca C.A., Cervato C., Frodeman R., Goodwin C., Liben L.S., Mogk D.W., Spangler T.C., Stillings N.A., Titus S. How geoscientists think and learn. EOS Trans. AGU 2009, 90. http://dx.doi.org/10.1029/2009EO310001.
187. Kato S. Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115:97-114. http://dx.doi.org/10.1007/S00401-007-0308-4.
188. Kenny E.E., Timpson N.J., Sikora M., Yee M.-C., Moreno-Estrada A.S., Eng C., Huntsman S., Burchard E.G.L., Stoneking M., Bustamante C.D., Myles S. Melanesian Blond hair is caused by an amino acid change in TYRP1. Science 2012, 336:554. http://www.sciencemag.org/Content/336/6081/554.Abstract.
189. Kirschner M.W., Gerhart J.C. The Plausibility of Life 2006, Yale University Press, New Haven.
190. Kitano H. Computational systems biology. Nature 2002, 420:206-210. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d12432404.
191. Kitano H. Systems biology: a brief overview. Science 2002, 295:1662-1664. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d11872829.
192. Kitano H. Arobustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. 2007, 6:202-210. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d17318209.
193. Klein S., Huber S. Sex differences in susceptibility to viral infection. Sex Hormones and Immunity to Infection 2010, 93-122. Springer-Verlag, Berlin. S. Klein, C. Roberts (Eds.).
194. Kleinman C. Of Mice and Mandates October 2, 1997, http://www.acsh.org/Wp-Content/Uploads/2012/04/20040329_Mice.Pdf.
195. Koch C. Systems biology. Modular biological complexity. Science 2012, 337:531-532. http://www.ncbi.nlm.nih.gov/Pubmed/22859475.
196. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d15286737.
197. Kolata G. Mice Fall Short as Test Subjects for Humans' Deadly Ills February 16, 2013, February 11, 2013. http://www.nytimes.com/2013/02/12/Science/Testing-Of-Some-Deadly-Diseases-On-Mice-Mislead-Report-Says.Html.
198. Kopp J.B., Nelson G.W., Sampath K., Johnson R.C., Genovese G., An P., Friedman D., Briggs W., Dart R., Korbet S., Mokrzycki M.H., Kimmel P.L., Limou S., Ahuja T.S., Berns J.S., Fryc J., Simon E.E., Smith M.C., Trachtman H., Michel D.M., Schelling J.R., Vlahov D., Pollak M., Winkler C.A. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J.Am. Soc. Nephrol. 2011, 22:2129-2137. http://jasn.asnjournals.org/Content/Early/2011/10/06/ASN.2011040388.Abstract.
199. Kummar S., Kinders R., Rubinstein L., Parchment R.E., Murgo A.J., Collins J., Pickeral O., Low J., Steinberg S.M., Gutierrez M., Yang S., Helman L., Wiltrout R., Tomaszewski J.E., Doroshow J.H. Compressing drug development timelines in oncology using phase '0' trials. Nat. Rev. Cancer 2007, 7:131-139. http://www.ncbi.nlm.nih.gov/Pubmed/17251919.
200. Kupiec J.J. On the lack of specificity of proteins and its consequences for a theory of biological organization. Prog. Biophys. Mol. Biol. 2010, 102:45-52. http://www.ncbi.nlm.nih.gov/Pubmed/19917305.
201. Kurakin A. Self-organization vs watchmaker: stochastic gene expression and cell differentiation. Dev. Genes Evol. 2005, 215:46-52. http://www.ncbi.nlm.nih.gov/Pubmed/15645318.
202. Lafollette H., Shanks N. Brute Science: Dilemmas of Animal Experimentation 1996, Routledge, London and New York.
203. Lambrechts D., Poesen K., Fernandez-Santiago R., Al-Chalabi A., Del Bo R., Van Vught P.W., Khan S., Marklund S.L., Brockington A., Van Marion I., Anneser J., Shaw C., Ludolph A.C., Leigh N.P., Comi G.P., Gasser T., Shaw P.J., Morrison K.E., Andersen P.M., Van Den Berg L.H., Thijs V., Siddique T., Robberecht W., Carmeliet P. Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. J.Med. Genet. 2009, 46:840-846. http://www.ncbi.nlm.nih.gov/Pubmed/18413368.
204. Lazzarini L., Overgaard K.A., Conti E., Shirtliff M.E. Experimental osteomyelitis: what have we learned from animal studies about the systemic treatment of osteomyelitis?. J.Chemother. 2006, 18:451-460. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d17127219.
205. Leaf C. Why we are losing the war on cancer. Fortune 2004, 77-92. http://money.cnn.com/Magazines/Fortune/Fortune_Archive/2004/03/22/365076/Index.Htm.
206. Lewin R. Complexity: Life at the Edge of Chaos 1999, The University Of Chicago Press, Chicago.
207. Lin T.M., Chen C.J., Wu M.M., Yang C.S., Chen J.S., Lin C.C., Kwang T.Y., Hsu S.T., Lin S.Y., Hsu L.C. Hepatitis B virus markers in Chinese twins. Anticancer Res. 1989, 9:737-741. http://www.ncbi.nlm.nih.gov/Pubmed/2764519.
208. Lippman N., Stein K.M., Lerman B.B. Nonlinear forecasting and the dynamics of cardiac rhythm. J.Electrocardiol. 1995, 28(Suppl.):65-70. http://www.ncbi.nlm.nih.gov/Pubmed/8656131.
209. Litchfield J.T. Symposium on clinical drug evaluation and human pharmacology. XVI. Evaluation of the safety of new drugs by means of tests in animals. Clin. Pharmacol. Ther. 1962, 3:665-672. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d14465857.
210. Litchfield J.T. Predictability of conventional animal toxicity tests. Ann. N. Y. Acad. Sci. 1965, 123:268-272. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d14329209.
211. Lombardi F. Chaos theory, heart rate variability, and arrhythmic mortality. Circulation 2000, 101:8-10. http://www.ncbi.nlm.nih.gov/Pubmed/10618296.
212. Lowe C.B., Kellis M., Siepel A., Raney B.J., Clamp M., Salama S.R., Kingsley D.M., Lindblad-Toh K., Haussler D. Three periods of regulatory innovation during vertebrate evolution. Science 2011, 333:1019-1024. http://www.ncbi.nlm.nih.gov/Pubmed/21852499.
213. Lumley C. Clinical toxicity: could it have been predicted? Premarketing experience. Animal Toxicity Studies: Their Relevance for Man 1990, 49-56. Quay, London. C. Lumley, S. Walker (Eds.).
214. Luttge U. Modularity and emergence: biology's challenge in understanding life. Plant Biol. 2012, 14:865-871. http://www.ncbi.nlm.nih.gov/Pubmed/23016697.
215. Mahmood I. Can absolute oral bioavailability in humans be predicted from animals? A comparison of allometry and different indirect methods. Drug Metab. Drug Interact. 2000, 16:143-155. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d10962646.
216. Maiti S., Kumar K.H.B.G., Castellani C.A., O'Reilly R., Singh S.M. Ontogenetic de novo copy number variations (CNVs) as a source of genetic individuality: studies on two families with MZD twins for schizophrenia. Plos ONE 2011, 6:E17125. http://dx.doi.org/10.1371%252Fjournal.Pone.0017125.
217. Mancuso R., Olivan S., Mancera P., Pasten-Zamorano A., Manzano R., Casas C., Osta R., Navarro X. Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Off. Publ. World Fed. Neurol. Res. Group Motor Neuron Dis. 2012, 13:302-310. http://www.ncbi.nlm.nih.gov/Pubmed/22424126.
218. Manson S.M. Simplifying complexity: a review of complexity theory. Geoforum 2001, 32:405-414.
219. Manson J., Wise D. Teratogens, Casarett and Doull's Toxicology 1993, 228.
220. Markou A., Chiamulera C., Geyer M.A., Tricklebank M., Steckler T. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2009, 34:74-89. http://www.ncbi.nlm.nih.gov/Pubmed/18830240.
221. Marsoni S., Hoth D., Simon R., Leyland-Jones B., De Rosa M., Wittes R.E. Clinical drug development: an analysis of Phase II trials, 1970-1985. Cancer Treat. Rep. 1987, 71:71-80. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d3791270.
222. Matsumoto S., Kusaka H., Ito H., Shibata N., Asayama T., Imai T. Sporadic amyotrophic lateral sclerosis with dementia and Cu/Zn superoxide dismutase-positive Lewy body-like inclusions. Clin. Neuropathol. 1996, 15:41-46. http://www.ncbi.nlm.nih.gov/Pubmed/8998856.
223. Mayr E. This is Biology: the Science of the Living World 1998, Belknap Press.
224. Mayr E. What Evolution is 2002, Basic Books, New York.
225. Mazzocchi F. Complexity and the reductionism-holism debate in systems biology. Wiley Interdiscip. Rev. Syst. Biol. Med. 2012, 4:413-427. http://www.ncbi.nlm.nih.gov/Pubmed/22761024.
226. Mclean C.Y., Reno P.L., Pollen A.A., Bassan A.I., Capellini T.D., Guenther C., Indjeian V.B., Lim X., Menke D.B., Schaar B.T., Wenger A.M., Bejerano G., Kingsley D.M. Human-specific loss of regulatory DNA and the evolution of human-specific traits. Nature 2011, 471:216-219. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d21390129.
227. M.E. Models that better mimic human cancer. Nature Biotechnology 2010, 28, vii. inthis issue.
228. Melham T. Modelling, abstraction, and computation in systems biology: a view from computer science. Prog. Biophys. Mol. Biol. 2012, http://www.ncbi.nlm.nih.gov/Pubmed/22975313.
229. Melham T., Bard J., Werner E., Noble D. Conceptual foundations of systems biology. Prog. Biophys. Mol. Biol. 2012, http://www.ncbi.nlm.nih.gov/Pubmed/23200782.
230. Meyer U.A. Genetic polymorphisms of drug metabolism. Fundam. Clin. Pharmacol. 1990, 4:595-615. http://www.ncbi.nlm.nih.gov/Pubmed/1982880.
231. Meymandi A. The science of epigenetics. Psychiatry (Edgmont) 2010, 7:40-41. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d20436775.
232. Millan M.J., Agid Y., Brune M., Bullmore E.T., Carter C.S., Clayton N.S., Connor R., Davis S., Deakin B., Derubeis R.J., Dubois B., Geyer M.A., Goodwin G.M., Gorwood P., Jay T.M., Joels M., Mansuy I.M., Meyer-Lindenberg A., Murphy D., Rolls E., Saletu B., Spedding M., Sweeney J., Whittington M., Young L.J. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug Discov. 2012, 11:141-168. http://www.ncbi.nlm.nih.gov/Pubmed/22293568.
233. Miquel P.A. Extended physics as a theoretical framework for systems biology?. Prog. Biophys. Mol. Biol. 2011, 106:348-352. http://www.ncbi.nlm.nih.gov/Pubmed/21463648.
234. Misch E.A., Berrington W.R., Vary J.C., Hawn T.R. Leprosy and the human genome. Microbiol. Mol. Biol. Rev. MMBR 2010, 74:589-620. http://www.ncbi.nlm.nih.gov/Pubmed/21119019.
235. Morange M. Asuccessful form for reductionism. The Biochemist 2001, 23:37-39.
236. Morgan P., Graaf P.H.V.D., Arrowsmith J., Feltner D.E., Drummond K.S., Wegner C.D., Street S.D.A. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov. Today 2012, 17:419-424.
237. Moss L. The question of questions: what is a gene? Comments on Rolston and Griffiths & Stotz. Theor. Med. Bioeth. 2006, 27:523-534. http://www.ncbi.nlm.nih.gov/Pubmed/17139449.
238. Mueller G.B., Olsson L. Epigenesis and epigenetics. Keywords and Concepts in Evolutionary Developmental Biology 2003, 120. Harvard University Press. B.K. Hall, W.M. Olson (Eds.).
239. Mullard A. Marc Kirschner. Nat. Rev. Drug Discov. 2011, 10:894. http://dx.doi.org/10.1038/Nrd3613.
240. Muqit M.M., Larner A.J., Sweeney M.G., Sewry C., Stinton V.J., Davis M.B., Healy D.G., Payne S.J., Chotai K., Wood N.W., Lane R.J. Multiple mitochondrial DNA deletions in monozygotic twins with OPMD. J.Neurol. Neurosurg. Psychiatry 2008, 79:68-71.
241. Nakajima T. Probability in biology: overview of a comprehensive theory of probability in living systems. Prog. Biophys. Mol. Biol. 2013, http://www.ncbi.nlm.nih.gov/Pubmed/23562914.
242. Nebert D. Pharmacogenetics: 65 candles on the cake. Pharmacogenetics 1997, 7:435-440.
243. Nebert D.W., Ingelman-Sundberg M., Daly A.K. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their Functional importance, and nomenclature issues. Drug Metab. Rev. 1999, 31:467-487. http://www.ncbi.nlm.nih.gov/Pubmed/10335448.
244. News in brief. Nat. Rev. Drug Discov. 2011, 10:889. News & Analysis. http://dx.doi.org/10.1038/Nrd3609.
245. Nicolis G., Prigogine I. Self-organisation in Nonequilibrium Systems: from Dissipative Structures to Order through Fluctuations 1977, John Wiley & Sons, New York.
246. Nirmalananthan N., Greensmith L. Amyotrophic lateral sclerosis: recent advances and future therapies. Curr. Opin. Neurol. 2005, 18:712-719. http://www.ncbi.nlm.nih.gov/Pubmed/16280684.
247. Noble D. From genes to whole organs: connecting biochemistry to physiology. Novartis Found. Symp. 2001, 239:111-123. Discussion 123-8, 150-9. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d11529307.
248. Noble D. Genes and causation. Philos. Transact. A Math. Phys. Eng. Sci. 2008, 366:3001-3015. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d18559318.
249. Northrop R.B. Introduction to Complexity and Complex Systems 2011, CRC Press, Boca Raton.
250. Novella S. Connectomics 2011, http://theness.com/Neurologicablog/Index.Php/Connectomics/.
251. Novella S. Mouse Models of Sepsis Challenged 2013, http://www.sciencebasedmedicine.org/Index.Php/Mouse-Model-Of-Sepsis-Challenged/.
252. Novella S. The Skeptics Guide to the Universe 2013, #395. February 9, 2013. http://www.theskepticsguide.org/Archive/Podcastinfo.Aspx%3fMid%3d1%26Pid%3d395.
253. Novikoff A.B. The concept of integrative levels and biology. Science 1945, 101:209-215. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d17814095.
254. Focus on sepsis. Nat Med. 2012, 18:997. News, http://dx.doi.org/10.1038/nm0712-997.
255. O'Collins V.E., Macleod M.R., Donnan G.A., Horky L.L., Van Der Worp B.H., Howells D.W. 1026 experimental treatments in acute stroke. Ann. Neurol. 2006, 59:467-477. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d16453316.
256. Ogihara N.L., Parge H.E., Hart P.J., Weiss M.S., Goto J.J., Crane B.R., Tsang J., Slater K., Roe J.A., Valentine J.S., Eisenberg D., Tainer J.A. Unusual trigonal-planar copper configuration revealed in the atomic structure of yeast copper-zinc superoxide dismutase. Biochemistry 1996, 35:2316-2321. http://www.ncbi.nlm.nih.gov/Pubmed/8652572.
257. Ollikainen M., Craig J.M. Epigenetic discordance at imprinting control regions in twins. Epigenomics 2011, 3:295-306.
258. Answering "Scientific" Arguments of Animal Rights Extremists 2010, Orac. http://scienceblogs.com/Insolence/2010/03/Answering_Scientific_Arguments_Of_An.Php%3fUtm_Source%3dNetworkbanner%26Utm_Medium%3dLink.
259. Oreskes N., Conway E.M.M. Merchants of Doubt. How a Handful of Scientists Obscrued the Truth on Issues from Tobacco Smoke to Global Warming 2011, Bloomsbury Press, New York.
260. Ottino J.M. Engineering complex systems. Nature 2004, 427:399. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d14749808.
261. Pan L., Yoshii Y., Otomo A., Ogawa H., Iwasaki Y., Shang H.F., Hadano S. Different human copper-zinc superoxide dismutase mutants, SOD1G93A and SOD1H46R, exert distinct harmful effects on gross phenotype in mice. Plos ONE 2012, 7:E33409. http://www.ncbi.nlm.nih.gov/Pubmed/22438926.
262. Pankevich D.E., Wizemann T.M., Altevogt B.M. Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary 2013, National Academies Press, Washington DC.
263. Parge H.E., Hallewell R.A., Tainer J.A. Atomic structures of wild-type and thermostable mutant recombinant human Cu, Zn superoxide dismutase. Proc. Natl. Acad. Sci. U S A 1992, 89:6109-6113. http://www.ncbi.nlm.nih.gov/Pubmed/1463506.
264. Park B.K., Boobis A., Clarke S., Goldring C.E.P., Jones D., Kenna J.G., Lambert C., Laverty H.G., Naisbitt D.J., Nelson S., Nicoll-Griffith D.A., Obach R.S., Routledge P., Smith D.A., Tweedie D.J., Vermeulen N., Williams D.P., Wilson I.D., Baillie T.A. Managing the challenge of chemically reactive metabolites in drug development. Nat. Rev. Drug Discov. 2011, 10:292-306. http://dx.doi.org/10.1038/Nrd3408.
265. Parkinson C., Grasso P. The use of the dog in toxicity tests on pharmaceutical compounds. Hum. Exp. Toxicol. 1993, 12:99-109. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d8096722.
266. Paul J.R. AHistory of Poliomyelitis 1971, Yale University Press, New Haven.
267. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., Schacht A.L. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9:203-214. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d20168317.
268. Paxton J.W. The allometric approach for interspecies scaling of pharmacokinetics and toxicity of anti-cancer drugs. Clin. Exp. Pharmacol. Physiol. 1995, 22:851-854. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d8593743.
269. Pearson H. Surviving a knockout blow. Nature 2002, 415:8-9. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d11780081.
270. Peviani M., Caron I., Pizzasegola C., Gensano F., Tortarolo M., Bendotti C. Unraveling the complexity of amyotrophic lateral sclerosis: recent advances from the transgenic mutant SOD1 mice. CNS Neurol. Disord. Drug Targets 2010, 9:491-503. http://www.ncbi.nlm.nih.gov/Pubmed/20522008.
271. Pirmohamed M. Pharmacogenetics: past, present and future. Drug Discov. Today 2011, 16:852-861.
272. Dalmatian Bladder Stones Caused by Gene that Regulates Uric Acid in Humans 2008, Plos Press Release. http://www.eurekalert.org/Pub_Releases/2008-11/Plos-Dbs110408.Php.
273. Popper K. Conjectures and Refutations: the Growth of Scientific Knowledge 2002, (Routledge Classics), Routledge, New York. second ed.
274. Ptashne M., Gann A. Genes & Signals 2002, Cold Springs Harbor Laboratory Press.
275. Qiu J. Epigenetics: unfinished symphony. Nature 2006, 441:143-145. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d16688142.
276. Rangarajan A., Weinberg R.A. Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat. Rev. Cancer 2003, 3:952-959. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d14737125.
277. Redler R.L., Dokholyan N.V. The complex molecular biology of amyotrophic lateral sclerosis (ALS). Prog. Mol. Biol. Transl. Sci. 2012, 107:215-262. http://www.ncbi.nlm.nih.gov/Pubmed/22482452.
278. Rohan R.M., Fernandez A., Udagawa T., Yuan J., D'Amato R.J. Genetic heterogeneity of angiogenesis in mice. FASEB J. 2000, 14:871-876. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d10783140.
279. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
280. Rosenblum I., Wohl A., Stein A.A. Studies in cardiac necrosis. 3. Metabolic effects of sympathomimetic amines producing cardiac lesions. Toxicol. Appl. Pharmacol. 1965, 7:344-351. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d14298025.
281. Rosenblum I., Wohl A., Stein A.A. Studies in cardiac necrosis. I. Production of cardiac lesions with sympathomimetic amines. Toxicol. Appl. Pharmacol. 1965, 7:1-8. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d14256598.
282. Rosenblum I., Wohl A., Stein A.A. Studies in cardiac necrosis. II. Cardiovascular effects of sympathomimetic amines producing cardiac lesions. Toxicol. Appl. Pharmacol. 1965, 7:9-17. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d14256610.
283. Roses A.D. Pharmacogenetics and the practice of medicine. Nature 2000, 405:857-865. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d10866212.
284. Roth R.H. Dopamine Deficit and Schizophrenia 2003, Yale, 5R01MH057483-06.
285. Rothstein J.D. Preclinical studies: how much can we rely on?. Amyotroph. Lateral Scler. Other Motor Neuron Disord. Off. Publ. World Fed. Neurol., Res. Group Motor Neuron Dis. 2004, 5(Suppl.1):22-25. http://www.ncbi.nlm.nih.gov/Pubmed/15512864.
286. Rothstein J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 2009, 65(Suppl.1):S3-S9.
287. Rothwell P.M. Funding for practice-oriented clinical research. Lancet 2006, 368:262-266. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d16860680.
288. Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N.Engl. J. Med. 2001, 344:1688-1700. http://www.ncbi.nlm.nih.gov/Pubmed/11386269.
289. Rudczynski A.B. Letter 2011, New Haven Register. http://www.nhregister.com/Articles/2011/03/25/Opinion/Doc4d8bb9186a82b265857273.Txt.
290. Rypniewski W.R., Mangani S., Bruni B., Orioli P.L., Casati M., Wilson K.S. Crystal structure of reduced bovine erythrocyte superoxide dismutase at 1.9A resolution. J.Mol. Biol. 1995, 251:282-296. http://www.ncbi.nlm.nih.gov/Pubmed/7643403.
291. Salsburg D. The lifetime feeding study in mice and rats - an examination of its validity as a bioassay for human carcinogens. Fundam. Appl. Toxicol. 1983, 3:63-67. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d6884625.
292. Sankar U. The delicate toxicity balance in drug discovery. The Scientist 2005, 19:32.
293. Sarkar S.K. Molecular imaging approaches. Drug Discov. World 2009, 33-38.
294. Schadt E.E., Sachs A., Friend S. Embracing complexity, inching closer to reality. Sci. STKE 2005, 2005:Pe40. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d16077086.
295. Schnabel J. Neuroscience: standard model. Nature 2008, 454:682-685. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d18685674.
296. Schroederc M.J. Crisis in science: in search for new theoretical foundations. Prog. Biophys. Mol. Biol. 2013, http://www.ncbi.nlm.nih.gov/Pubmed/23541469.
297. Scott R.C., Batten P.L., Clowes H.M., Jones B.K., Ramsey J.D. Further validation of an invitro method to reduce the need for invivo studies for measuring the absorption of chemicals through rat skin. Fundam. Appl. Toxicol. 1992, 19:484-492. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d1426705.
298. Scott S., Kranz J.E., Cole J., Lincecum J.M., Thompson K., Kelly N., Bostrom A., Theodoss J., Al-Nakhala B.M., Vieira F.G., Ramasubbu J., Heywood J.A. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph. Lateral Scler. 2008, 9:4-15.
299. Seely A.J., Christou N.V. Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems. Crit. Care Med. 2000, 28:2193-2200. http://www.ncbi.nlm.nih.gov/Pubmed/10921540.
300. Seetharaman S.V., Taylor A.B., Holloway S., Hart P.J. Structures of mouseSOD1 and human/mouse SOD1 chimeras. Arch. Biochem. Biophys. 2010, 503:183-190.
301. Sellers R.S., Senese P.B., Khan K.N. Interspecies differences in the nephrotoxic response to cyclooxygenase inhibition. Drug Chem. Toxicol. 2004, 27:111-122. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d15198071.
302. Seok J., Warren H.S., Cuenca A.G., Mindrinos M.N., Baker H.V., Xu W., Richards D.R., Mcdonald-Smith G.P., Gao H., Hennessy L., Finnerty C.C., Lopez C.M., Honari S., Moore E.E., Minei J.P., Cuschieri J., Bankey P.E., Johnson J.L., Sperry J., Nathens A.B., Billiar T.R., West M.A., Jeschke M.G., Klein M.B., Gamelli R.L., Gibran N.S., Brownstein B.H., Miller-Graziano C., Calvano S.E., Mason P.H., Cobb J.P., Rahme L.G., Lowry S.F., Maier R.V., Moldawer L.L., Herndon D.N., Davis R.W., Xiao W., Tompkins R.G. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U S A 2013, http://www.ncbi.nlm.nih.gov/Pubmed/23401516.
303. Serrano D., Lazzeroni M., Zambon C.F., Macis D., Maisonneuve P., Johansson H., Guerrieri-Gonzaga A., Plebani M., Basso D., Gjerde J., Mellgren G., Rotmensz N., Decensi A., Bonanni B. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian tamoxifen prevention trial. Pharmacogenomics J. 2011, 11:100-107. http://dx.doi.org/10.1038/Tpj.2010.17.
304. Shah V.P., Flynn G.L., Guy R.H., Maibach H.I., Schaefer H., Skelly J.P., Wester R.C., Yacobi A. Workshop report on invivo percutaneous penetration/absorption. Washington D.C., May 1-3, 1989. Skin Pharmacol. 1991, 4:220-228. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d1685087.
305. Shanks N., Greek R. Animal Models in Light of Evolution 2009, Brown Walker, Boca Raton.
306. Shanks N., Greek R., Greek J. Are animal models predictive for humans?. Philos. Ethics Humanit. Med. 2009, 4:2. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d19146696.
307. Sharp P.A., Langer R. Promoting convergence in biomedical science. Science 2011, 333:527. http://www.sciencemag.org/Content/333/6042/527.Short.
308. Shepard T., Lemire R. Catalog of Teratogenic Agents 2004, Johns Hopkins, Baltimore. eleventh ed.
309. Shibata N., Hirano A., Kobayashi M., Sasaki S., Kato T., Matsumoto S., Shiozawa Z., Komori T., Ikemoto A., Umahara T., et al. Cu/Zn superoxide dismutase-like immunoreactivity in Lewy body-like inclusions of sporadic amyotrophic lateral sclerosis. Neurosci. Lett. 1994, 179:149-152. http://www.ncbi.nlm.nih.gov/Pubmed/7845611.
310. Shibata N., Asayama K., Hirano A., Kobayashi M. Immunohistochemical study on superoxide dismutases in spinal cords from autopsied patients with amyotrophic lateral sclerosis. Dev. Neurosci. 1996, 18:492-498. http://www.ncbi.nlm.nih.gov/Pubmed/8940623.
311. Sietsema W.K. The absolute oral bioavailability of selected drugs. Int. J. Clin. Pharmacol. Ther. Toxicol. 1989, 27:179-211. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d2654032.
312. Simon V. Wanted: women in clinical trials. Science 2005, 308:1517. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d15947140.
313. Sinha G. Another blow for ALS. Nat. Biotechnol. 2013, 31:185. http://www.ncbi.nlm.nih.gov/Pubmed/23471053.
314. Smith R.L., Caldwell J. Drug metabolism in non-human primates. Drug Metabolism - from Microbe to Man 1977, 331-356. Taylor & Francis, London. D.V. Parke, R.L. Smith (Eds.).
315. Smith W.E., Miller L., Elsasser R.E., Hubert D.D. Tests for carcinogenicity of asbestos. Ann. N. Y. Acad. Sci. 1965, 132:456-488. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d5219568.
316. Sole R., Goodwin B. Signs of Life: How Complexity Pervades Biology 2002, Basic Books, New York.
317. Soto A.M., Sonnenschein C., Maini P.K., Noble D. Systems biology and cancer. Prog. Biophys. Mol. Biol. 2011, 106:337-339. http://www.ncbi.nlm.nih.gov/Pubmed/21843772.
318. Spielman R.S., Bastone L.A., Burdick J.T., Morley M., Ewens W.J., Cheung V.G. Common genetic variants account for differences in gene expression among ethnic groups. Nat. Genet. 2007, 39:226-231. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d17206142.
319. SCRIP Reports 1994, PJB, New York. C. Spriet-Pourra, M. Auriche (Eds.).
320. Stamer U.M., Stuber F. The pharmacogenetics of analgesia. Expert Opin. Pharmacother. 2007, 8:2235-2245. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d17927480.
321. Stankiewicz P., Lupski J.R. Structural variation in the human genome and its role in disease. Annu. Rev. Med. 2010, 61:437-455.
322. Stathopulos P.B., Rumfeldt J.A., Scholz G.A., Irani R.A., Frey H.E., Hallewell R.A., Lepock J.R., Meiering E.M. Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis show enhanced formation of aggregates invitro. Proc. Natl. Acad. Sci. U S A 2003, 100:7021-7026. http://www.ncbi.nlm.nih.gov/Pubmed/12773627.
323. Stemwedel J. Some Preliminary Thoughts on the UCLA Panel Discussion on Animal-based Research 2010, http://scienceblogs.com/Ethicsandscience/2010/02/Some_Preliminary_Thoughts_On_T.Php.
324. Stolley P.D. Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am. Rev. Respir. Dis. 1972, 105:883-890. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d5032708.
325. Stolley P.D., Schinnar R. Fatal asthma. Lancet 1979, 2:897. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d90979.
326. Stoloff L. An analysis of the 1987 list of IARC-identified human carcinogens and the correlated animal studies. Regul. Toxicol. Pharmacol. RTP 1992, 15:10-13. http://www.ncbi.nlm.nih.gov/Pubmed/1553406.
327. Strange R.W., Antonyuk S.V., Hough M.A., Doucette P.A., Valentine J.S., Hasnain S.S. Variable metallation of human superoxide dismutase: atomic resolution crystal structures of Cu-Zn, Zn-Zn and as-isolated wild-type enzymes. J.Mol. Biol. 2006, 356:1152-1162. http://www.ncbi.nlm.nih.gov/Pubmed/16406071.
328. Stump D.S., Vandewoude S. Animal models for HIV AIDS: a comparative review. Comp. Med. 2007, 57:33-43. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d17348289.
329. Suggitt M., Bibby M.C. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2005, 11:971-981. http://www.ncbi.nlm.nih.gov/Pubmed/15709162.
330. Suter K. What can Be learned from case studies? The company approach. Animal Toxicity Studies: Their Relevance for Man 1990, 71-78. Quay, Lancaster. C. Lumley, S. Walker (Eds.).
331. Tainer J.A., Getzoff E.D., Beem K.M., Richardson J.S., Richardson D.C. Determination and analysis of the 2A - Structure of copper, zinc superoxide dismutase. J.Mol. Biol. 1982, 160:181-217. http://www.ncbi.nlm.nih.gov/Pubmed/7175933.
332. Tandon, A., April 12, 2011. August 8, 2011. http://www.tribuneindia.com/2011/20110808/Main1.Htm.
333. Tomatis L., Agthe C., Bartsch H., Huff J., Montesano R., Saracci R., Walker E., Wilbourn J. Evaluation of the carcinogenicity of chemicals: a review of the monograph program of the International Agency for research on cancer (1971 to 1977). Cancer Res. 1978, 38:877-885. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d346205.
334. Van Regenmortel M. Aparadigm shift is needed in proteomics: 'structure determines function' should Be replaced by binding determines function'. J.Mol. Recognit.: JMR 2002, 15:349-351. http://www.ncbi.nlm.nih.gov/Pubmed/12501156.
335. Van Regenmortel M. Pitfalls Otf reductionism in immunology. Promises and Limits of Reductionism in the Biomedical Sciences 2002, 47-66. John Wiley & Sons Ltd., Chichester. M. Van Regenmortel, D.L. Hull (Eds.).
336. Van Regenmortel M. Reductionism and the search for structure-function relationships in antibody molecules. J.Mol. Recognit.: JMR 2002, 15:240-247. http://www.ncbi.nlm.nih.gov/Pubmed/12447900.
337. Van Regenmortel M. Biological complexity emerges from the ashes of geneticreductionism. J.Mol. Recognit. 2004, 17:145-148. http://dx.doi.org/10.1002/Jmr.674.
338. Van Regenmortel M. Reductionism and complexity in molecular biology. Scientists now have the tools to unravel biological complexity and overcome the limitations of reductionism. EMBO Rep. 2004, 5:1016-1020. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d15520799.
339. Van Regenmortel M.H.V. Basic research in HIV vaccinology is hampered by reductionist thinking. Front. Immunol. 2012, 3. http://www.frontiersin.org/Journal/Abstract.Aspx%3fS%3d1247%26Name%3dImmunotherapies_And_Vaccines%26ART_DOI%3d10.3389/Fimmu.2012.00194.
340. Van Regenmortel M.H., Hull D.L. Promises and Limits of Reductionism in theBiomedical Sciences (Catalysts for Fine Chemical Synthesis) 2002, Wiley, West Sussex.
341. Vassar R. Alzheimer's therapy: a BACE in the hand?. Nat. Med. 2011, 17:932-933. http://dx.doi.org/10.1038/Nm0811-932.
342. Wald C., Wu C. Of mice and women: the bias in animal models. Science 2010, 327:1571-1572.
343. Walker R.M., Mcelligott T.F. Furosemide induced hepatotoxicity. J.Pathol. 1981, 135:301-314. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d7328448.
344. Wall R.J., Shani M. Are animal models as good as we think?. Theriogenology 2008, 69:2-9. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d17988725.
345. Walton K., Dorne J.L., Renwick A.G. Species-specific uncertainty factors for compounds eliminated principally by renal excretion in humans. Food Chem. Toxicol. 2004, 42:261-274. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d14667472.
346. Wang J., Slunt H., Gonzales V., Fromholt D., Coonfield M., Copeland N.G., Jenkins N.A., Borchelt D.R. Copper-binding-site-null SOD1 causes ALS in transgenic mice: aggregates of non-native SOD1 delineate a common feature. Hum. Mol. Genet. 2003, 12:2753-2764. http://www.ncbi.nlm.nih.gov/Pubmed/12966034.
347. Wang L., Deng H.X., Grisotti G., Zhai H., Siddique T., Roos R.P. Wild-type SOD1 overexpression accelerates disease onset of a G85R SOD1 mouse. Hum. Mol. Genet. 2009, 18:1642-1651. http://www.ncbi.nlm.nih.gov/Pubmed/19233858.
348. Wang D., Guo Y., Wrighton S.A., Cooke G.E., Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011, 11:274-286. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d20386561.
349. Watanabe M., Dykes-Hoberg M., Culotta V.C., Price D.L., Wong P.C., Rothstein J.D. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol. Dis. 2001, 8:933-941. http://www.ncbi.nlm.nih.gov/Pubmed/11741389.
350. Weatherall M. An end to the search for new drugs?. Nature 1982, 296:387-390.
351. Weaver J.L., Staten D., Swann J., Armstrong G., Bates M., Hastings K.L. Detection of systemic hypersensitivity to drugs using standard guinea pig assays. Toxicology 2003, 193:203-217. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d14599760.
352. Werner E. History of the seminar on the conceptual foundations of systems biology. Prog. Biophys. Mol. Biol. 2012, http://www.ncbi.nlm.nih.gov/Pubmed/23262312.
353. Wilke R.A., Dolan M.E. Genetics and variable drug response. JAMA: J. Am. Med. Assoc. 2011, 306:306-307. http://jama.ama-assn.org/Content/306/3/306.Short.
354. Williams G. Chaos Theory Tamed 1997, Joseph Henry Press, Washington, D.C.
355. Willyard C. Blue's clues. Nat. Med. 2007, 13:1272-1273. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d17987010.
356. Willyard C. HIV gender clues emerge. Nat. Med. 2009, 15:830. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d19661976.
357. Wolkenhauer O., Fell D., De Meyts P., Bluthgen N., Herzel H., Le Novere N., Hofer T., Schurrle K., Van Leeuwen I. Sysbiomed report: advancing systems biology for medical applications. IET Syst. Biol. 2009, 3:131-136. http://www.ncbi.nlm.nih.gov/Pubmed/19449974.
358. Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., Price D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995, 14:1105-1116. http://www.ncbi.nlm.nih.gov/Pubmed/7605627.
359. Wong A.H., Gottesman, Petronis A. Phenotypic differences in genetically identical organisms: the epigenetic perspective. Hum. Mol. Genet. 2005, 14:R11-R18. Spec No 1. http://www.ncbi.nlm.nih.gov/Entrez/Query.Fcgi%3fCmd%3dRetrieve%26Db%3dPubmed%26Dopt%3dCitation%26List_Uids%3d15809262.
360. ALS Online Genetics Database February 15, 2013, World Federation of Neurology and European Network to Cure ALS. http://alsod.iop.kcl.ac.uk/Als/.
361. Wynn J. What future for regulation? UK Committee's role disputed. Nature 1982, 299:387. http://www.ncbi.nlm.nih.gov/Pubmed/11643800.
362. Yucesoy B., Johnson V.J., Fluharty K., Kashon M.L., Slaven J.E., Wilson N.W., Weissman D.N., Biagini R.E., Germolec D.R., Luster M.I. Influence of cytokine gene variations on immunization to childhood vaccines. Vaccine 2009, 27:6991-6997.
363. Yuen J. Ths CEO Criticized for Links to Animal Testing October 2, 2011, http://m.torontosun.com/2011/09/23/Ths-Ceo-Criticized-For-Links-To-Animal-Testing%3fNoimage.
364. Zhao J., Goldberg J., Bremner J.D., Vaccarino V. Global DNA methylation isassociated with insulin resistance: a monozygotic twin study. Diabetes 2012, 61:542-546.
365. Zielinska E. Building a better mouse. The Scientist 2010, 24:34-38.